# Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure

> **NCT05566600** · EARLY_PHASE1 · UNKNOWN · sponsor: **HELP Therapeutics Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Ischemic Heart Failure
- Chronic Heart Failure

## Interventions

- **BIOLOGICAL:** Human (allogeneic) iPS-cell-derived cardiomyocyte

## Key facts

- **NCT ID:** NCT05566600
- **Lead sponsor:** HELP Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-09
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05566600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05566600, "Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05566600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*